Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BROMOCRIPTINE

Form:

4 of 4 products shown

2 general benefit · 2 not a benefit

Other products in the same Health Canada class (G02CB, N04B, N04BC) — coverage varies; not interchangeable

  • Ropinirole (ReQuip): general benefit, Not a benefit
  • Cabergoline (Dostinex): limited Use 656
  • Quinagolide (Norprolac): limited Use 405
  • Amantadine (Symmetrel): general benefit, Not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, Limited Use, Not a benefit

2 more in the class list below

Bromocriptine · DIN 02087324 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bromocriptine · DIN 02087324 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-01-13 · brand BROMOCRIPTINE · ATC N04BC01 BROMOCRIPTINE · form Tablet · route Oral · ingredients BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) 2.5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Bromocriptine: Formulary list price $1.0800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16195 · Verify on the e-Formulary ↗ (DIN 02087324)

Source record
DIN 02087324: Bromocriptine Raw flags: sec3=Y Item: 920000029; group id 900; item number 2159; lccId None; manufacturer id AAP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.0800; ministry $1.0800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02087324 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16195
Interchangeable products
Parlodel · DIN 00371033 · not recorded
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-09, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02087324
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bromocriptine · DIN 02230454 · 5mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bromocriptine · DIN 02230454 Manufacturer: A A Pharma Inc.; listing date 1997-08-28 Health Canada: Marketed since 2012-10-17 · brand BROMOCRIPTINE · ATC N04BC01 BROMOCRIPTINE · form Capsule · route Oral · ingredients BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) 5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Bromocriptine: Formulary list price $1.7097/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7097 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49403 · Verify on the e-Formulary ↗ (DIN 02230454)

Source record
DIN 02230454: Bromocriptine Raw flags: sec3=Y Item: 920000044; group id 900; item number 2158; lccId None; manufacturer id AAP Source form: Cap; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $1.7097; ministry $1.7097 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230454 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49403
Interchangeable products
Parlodel · DIN 00568643 · not recorded
Shortage status: resolved shortage (ended 2020-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230454
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Parlodel · DIN 00371033 · 2.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Parlodel · DIN 00371033 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand PARLODEL TAB 2.5MG · ATC G02CB01 BROMOCRIPTINE · form Tablet · route Oral · ingredients BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) 2.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Parlodel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2539 · Verify on the e-Formulary ↗ (DIN 00371033)

Source record
DIN 00371033: Parlodel Raw flags: notABenefit=Y, sec3=Y Item: 920000029; group id 900; item number 2159; lccId None; manufacturer id NOV Source form: Tab; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00371033 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2539
Interchangeable products
Bromocriptine · DIN 02087324 · $1.0800
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00371033
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Parlodel · DIN 00568643 · 5mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-09 — choose a marketed DIN from the same-category list.Discontinued 2005-09-09 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-09-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Parlodel · DIN 00568643 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-09-09 · brand PARLODEL CAP 5MG · ATC G02CB01 BROMOCRIPTINE · form Capsule · route Oral · ingredients BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) 5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Parlodel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5155 · Verify on the e-Formulary ↗ (DIN 00568643)

Source record
DIN 00568643: Parlodel Raw flags: notABenefit=Y, sec3=Y Item: 920000044; group id 900; item number 2158; lccId None; manufacturer id NOV Source form: Cap; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00568643 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5155
Interchangeable products
Bromocriptine · DIN 02230454 · $1.7097
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00568643
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-09-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

CABERGOLINE

· 3 products · Limited Use, codes 656 · strengths: 0.5mg · Tab

QUINAGOLIDE HCL

· 1 products · Limited Use, codes 405 · strengths: 0.15mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acromegaly, parkinsons disease
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LANREOTIDE ACETATE LANREOTIDE ACETATE · General benefit 1 INDICATIONS SOMATULINE® AUTOGEL® [lanreotide (as lanreotide acetate) injection] is indicated for: • The long-term treatment of adult patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. PM: https://pdf.hres.ca/dpd_pm/00071957.PDF; date JUL 17, 2006; DIN 02283395; fetched 2026-09-10 Product monograph LEVODOPA & CARBIDOPA · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) 1 INDICATIONS APO-LEVOCARB (levodopa and carbidopa tablets) is indicated for the treatment of Parkinson's disease. PM: https://pdf.hres.ca/dpd_pm/00076848.PDF; date AUG 27, 2024; DIN 02195933; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS BROMOCRIPTINE (Bromocriptine Mesylate) is indicated for:  Galactorrhea with or without amenorrhea due to hyperprolactinemia.  Prolactin-dependent menstrual disorders and infertility: e.g. secondary amenorrhea, ovulatory insufficiency and short luteal phase.  Prolactin-secreting adenomas: as a treatment for inoperable macroadenomas or prior to surgery in order to facilitate removal, and as an alternative to surgery in patients with microadenomas.  Prolactin-dependent male hypogonadism.  Acromegaly: the first-line treatment of this condition is by surgery or radiotherapy. BROMOCRIPTINE (bromocriptine mesylate) may be a useful adjunct to such treatment, and can be used as monotherapy in special cases.  Parkinson’s Disease: BROMOCRIPTINE is effective when used as adjunct therapy to levodopa in the symptomatic management of Parkinson’s Disease. Used concomitantly with levodopa, bromocriptine facilitates the use of lower doses of levodopa in early disease and attenuates the rate of increase in the levodopa dosages on long-term usage. In this way the risk of long– term complications su… https://pdf.hres.ca/dpd_pm/00064762.PDF PM date: FEB 16, 2022 Source product: BROMOCRIPTINE; DIN 02087324; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Bromocriptine · DIN 02087324 Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-09, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02087324

Check this DIN again

Other review policies

For Parlodel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026